Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan

Katsuto Takenaka, Kazuya Shimoda, Naoyuki Uchida, Taizo Shimomura, Koji Nagafuji, Tadakazu Kondo, Hirohiko Shibayama, Takehiko Mori, Kensuke Usuki, Taichi Azuma, Yutaka Tsutsumi, Junji Tanaka, Hitomi Dairaku, Keitaro Matsuo, Keiya Ozawa, Mineo Kurokawa, Shunya Arai, Koichi Akashi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We conducted a 17-year nationwide survey (1999–2015) to elucidate the clinical outcomes of patients with primary myelofibrosis (PMF) in Japan. Questionnaires were sent annually to approximately 500 hematology departments. Newly diagnosed patients with PMF were enrolled in this study, and were followed up annually to collect prognostic information. Approximately 50 patients were enrolled per year, yielding a total of 780 patients with PMF included in this study. The median age at diagnosis was 66 years. At the time of analysis, the median survival duration was 47 months, and the 3-year overall survival rate was 59 %. Infection and disease transformation into acute leukemia were the most frequent causes of death. Of the proposed prognostic models for predicting the outcomes of PMF patients in Japan, the Dynamic International Prognostic Scoring System of PMF plus model was the most feasible. Forty-three patients received allogeneic hematopoietic stem cell transplantation (alloSCT) at a median of 343 days after diagnosis. This treatment significantly prolonged the survival of PMF patients, and the 3-year overall survival rate after first alloSCT was 84 %. A long-term registration study is required for further evaluation of prognosis and the impact of treatments on survival.

Original languageEnglish
Pages (from-to)59-69
Number of pages11
JournalInternational Journal of Hematology
Volume105
Issue number1
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Primary Myelofibrosis
Japan
Research
Hematopoietic Stem Cell Transplantation
Survival Rate
Survival
Hematology
Survival Analysis
Surveys and Questionnaires
Cause of Death
Leukemia
Therapeutics
Infection

Keywords

  • Long-term outcome
  • Myelofibrosis
  • Nationwide survey

ASJC Scopus subject areas

  • Hematology

Cite this

Clinical features and outcomes of patients with primary myelofibrosis in Japan : report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan. / Takenaka, Katsuto; Shimoda, Kazuya; Uchida, Naoyuki; Shimomura, Taizo; Nagafuji, Koji; Kondo, Tadakazu; Shibayama, Hirohiko; Mori, Takehiko; Usuki, Kensuke; Azuma, Taichi; Tsutsumi, Yutaka; Tanaka, Junji; Dairaku, Hitomi; Matsuo, Keitaro; Ozawa, Keiya; Kurokawa, Mineo; Arai, Shunya; Akashi, Koichi.

In: International Journal of Hematology, Vol. 105, No. 1, 01.01.2017, p. 59-69.

Research output: Contribution to journalArticle

Takenaka, K, Shimoda, K, Uchida, N, Shimomura, T, Nagafuji, K, Kondo, T, Shibayama, H, Mori, T, Usuki, K, Azuma, T, Tsutsumi, Y, Tanaka, J, Dairaku, H, Matsuo, K, Ozawa, K, Kurokawa, M, Arai, S & Akashi, K 2017, 'Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan', International Journal of Hematology, vol. 105, no. 1, pp. 59-69. https://doi.org/10.1007/s12185-016-2102-3
Takenaka, Katsuto ; Shimoda, Kazuya ; Uchida, Naoyuki ; Shimomura, Taizo ; Nagafuji, Koji ; Kondo, Tadakazu ; Shibayama, Hirohiko ; Mori, Takehiko ; Usuki, Kensuke ; Azuma, Taichi ; Tsutsumi, Yutaka ; Tanaka, Junji ; Dairaku, Hitomi ; Matsuo, Keitaro ; Ozawa, Keiya ; Kurokawa, Mineo ; Arai, Shunya ; Akashi, Koichi. / Clinical features and outcomes of patients with primary myelofibrosis in Japan : report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan. In: International Journal of Hematology. 2017 ; Vol. 105, No. 1. pp. 59-69.
@article{33db900ddaa74012ae95a43987adb1d1,
title = "Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan",
abstract = "We conducted a 17-year nationwide survey (1999–2015) to elucidate the clinical outcomes of patients with primary myelofibrosis (PMF) in Japan. Questionnaires were sent annually to approximately 500 hematology departments. Newly diagnosed patients with PMF were enrolled in this study, and were followed up annually to collect prognostic information. Approximately 50 patients were enrolled per year, yielding a total of 780 patients with PMF included in this study. The median age at diagnosis was 66 years. At the time of analysis, the median survival duration was 47 months, and the 3-year overall survival rate was 59 {\%}. Infection and disease transformation into acute leukemia were the most frequent causes of death. Of the proposed prognostic models for predicting the outcomes of PMF patients in Japan, the Dynamic International Prognostic Scoring System of PMF plus model was the most feasible. Forty-three patients received allogeneic hematopoietic stem cell transplantation (alloSCT) at a median of 343 days after diagnosis. This treatment significantly prolonged the survival of PMF patients, and the 3-year overall survival rate after first alloSCT was 84 {\%}. A long-term registration study is required for further evaluation of prognosis and the impact of treatments on survival.",
keywords = "Long-term outcome, Myelofibrosis, Nationwide survey",
author = "Katsuto Takenaka and Kazuya Shimoda and Naoyuki Uchida and Taizo Shimomura and Koji Nagafuji and Tadakazu Kondo and Hirohiko Shibayama and Takehiko Mori and Kensuke Usuki and Taichi Azuma and Yutaka Tsutsumi and Junji Tanaka and Hitomi Dairaku and Keitaro Matsuo and Keiya Ozawa and Mineo Kurokawa and Shunya Arai and Koichi Akashi",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/s12185-016-2102-3",
language = "English",
volume = "105",
pages = "59--69",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Clinical features and outcomes of patients with primary myelofibrosis in Japan

T2 - report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan

AU - Takenaka, Katsuto

AU - Shimoda, Kazuya

AU - Uchida, Naoyuki

AU - Shimomura, Taizo

AU - Nagafuji, Koji

AU - Kondo, Tadakazu

AU - Shibayama, Hirohiko

AU - Mori, Takehiko

AU - Usuki, Kensuke

AU - Azuma, Taichi

AU - Tsutsumi, Yutaka

AU - Tanaka, Junji

AU - Dairaku, Hitomi

AU - Matsuo, Keitaro

AU - Ozawa, Keiya

AU - Kurokawa, Mineo

AU - Arai, Shunya

AU - Akashi, Koichi

PY - 2017/1/1

Y1 - 2017/1/1

N2 - We conducted a 17-year nationwide survey (1999–2015) to elucidate the clinical outcomes of patients with primary myelofibrosis (PMF) in Japan. Questionnaires were sent annually to approximately 500 hematology departments. Newly diagnosed patients with PMF were enrolled in this study, and were followed up annually to collect prognostic information. Approximately 50 patients were enrolled per year, yielding a total of 780 patients with PMF included in this study. The median age at diagnosis was 66 years. At the time of analysis, the median survival duration was 47 months, and the 3-year overall survival rate was 59 %. Infection and disease transformation into acute leukemia were the most frequent causes of death. Of the proposed prognostic models for predicting the outcomes of PMF patients in Japan, the Dynamic International Prognostic Scoring System of PMF plus model was the most feasible. Forty-three patients received allogeneic hematopoietic stem cell transplantation (alloSCT) at a median of 343 days after diagnosis. This treatment significantly prolonged the survival of PMF patients, and the 3-year overall survival rate after first alloSCT was 84 %. A long-term registration study is required for further evaluation of prognosis and the impact of treatments on survival.

AB - We conducted a 17-year nationwide survey (1999–2015) to elucidate the clinical outcomes of patients with primary myelofibrosis (PMF) in Japan. Questionnaires were sent annually to approximately 500 hematology departments. Newly diagnosed patients with PMF were enrolled in this study, and were followed up annually to collect prognostic information. Approximately 50 patients were enrolled per year, yielding a total of 780 patients with PMF included in this study. The median age at diagnosis was 66 years. At the time of analysis, the median survival duration was 47 months, and the 3-year overall survival rate was 59 %. Infection and disease transformation into acute leukemia were the most frequent causes of death. Of the proposed prognostic models for predicting the outcomes of PMF patients in Japan, the Dynamic International Prognostic Scoring System of PMF plus model was the most feasible. Forty-three patients received allogeneic hematopoietic stem cell transplantation (alloSCT) at a median of 343 days after diagnosis. This treatment significantly prolonged the survival of PMF patients, and the 3-year overall survival rate after first alloSCT was 84 %. A long-term registration study is required for further evaluation of prognosis and the impact of treatments on survival.

KW - Long-term outcome

KW - Myelofibrosis

KW - Nationwide survey

UR - http://www.scopus.com/inward/record.url?scp=84991799968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991799968&partnerID=8YFLogxK

U2 - 10.1007/s12185-016-2102-3

DO - 10.1007/s12185-016-2102-3

M3 - Article

C2 - 27761702

AN - SCOPUS:84991799968

VL - 105

SP - 59

EP - 69

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 1

ER -